Necrolytic migratory erythema caused by pancreatic hyperglycemia with emphasis on therapeutic and prognosis:A case report  

作　　者：Shi-Ping Zhan 

机构地区：[1]Department of Dermatology,General Hospital of the Yangtze River Shipping,Wuhan Brain Hospital,Wuhan 430000,Hubei Province,China

出　　处：《World Journal of Clinical Cases》2024年第23期5404-5409,共6页世界临床病例杂志

摘　　要：BACKGROUNDWith the incidence of pancreatic diseases increasing year by year,pancreatichyperglycemia,as one of the common complications,is gradually gaining attentionfor its impact on the skin health of patients.CASE SUMMARYThis was the case of an elderly female with clinical manifestations of necrolyticmigratory erythema,“three more and one less,”diabetes mellitus,hypertension,anemia,hypoproteinemia,and other syndromes,which had been misdiagnosedas eczema.Abdominal computed tomography showed a pancreatic caudal spaceoccupyinglesion,and the magnetic resonance scanning of the epigastric regionwith dynamic enhancement and diffusion-weighted imaging suggested a tumorof the pancreatic tail,which was considered to be a neuroendocrine tumor orcystadenoma.The patient was referred to a more equipped hospital for laparoscopicpancreatic tail resection.Post-surgery diagnosis revealed a neuroendocrinetumor in the tail of the pancreas.To date,the patient’s general condition is good,and she is still under close follow-up.CONCLUSIONNecrolytic migratory erythema can be induced by endocrine system tumors orendocrine metabolic abnormalities,with complex clinical manifestations,difficultdiagnosis,and easy misdiagnosis by dermatologists.The initial treatment principlesin dermatology include symptomatic supportive therapy and effectivedrugs to relieve skin lesions.After clarifying the etiology of glucagonoma,comprehensive treatment in collaboration with endocrinologists,generalsurgeons,and oncologists can help provide individualized treatment for patientsand improve their prognosis.

关 键 词：GLUCAGONOMA Necrolytic loosening of wandering erythema Treatment PROGNOSIS 

分 类 号：R576[医药卫生—消化系统] R574.5[医药卫生—内科学]